Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Clinical Determinants and Prognostic Implications of Right Ventricular Dysfunction in Pulmonary Hypertension Caused by Chronic Lung Disease.

Prins KW, Rose L, Archer SL, Pritzker M, Weir EK, Olson MD, Thenappan T.

J Am Heart Assoc. 2019 Jan 22;8(2):e011464. doi: 10.1161/JAHA.118.011464.

2.

Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again.

Prins KW, Thenappan T, Weir EK, Kalra R, Pritzker M, Archer SL.

J Am Heart Assoc. 2019 Jan 8;8(1):e011343. doi: 10.1161/JAHA.118.011343. No abstract available.

3.

Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide.

Rose L, Prins KW, Archer SL, Pritzker M, Weir EK, Misialek JR, Thenappan T.

J Heart Lung Transplant. 2019 Feb;38(2):145-155. doi: 10.1016/j.healun.2018.09.011. Epub 2018 Sep 14.

4.

Exacerbation of dystrophic cardiomyopathy by phospholamban deficiency mediated chronically increased cardiac Ca2+ cycling in vivo.

Law ML, Prins KW, Olander ME, Metzger JM.

Am J Physiol Heart Circ Physiol. 2018 Dec 1;315(6):H1544-H1552. doi: 10.1152/ajpheart.00341.2018. Epub 2018 Aug 17.

PMID:
30118340
5.

Disproportionate Right Ventricular Dysfunction and Poor Survival in Group 3 Pulmonary Hypertension.

Prins KW, Rose L, Archer SL, Pritzker M, Weir EK, Kazmirczak F, Misialek JR, Thenappan T.

Am J Respir Crit Care Med. 2018 Jun 1;197(11):1496-1499. doi: 10.1164/rccm.201712-2405LE. No abstract available.

6.

Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension.

Prins KW, Archer SL, Pritzker M, Rose L, Weir EK, Sharma A, Thenappan T.

J Heart Lung Transplant. 2018 Mar;37(3):376-384. doi: 10.1016/j.healun.2017.08.011. Epub 2017 Sep 1.

7.

Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis.

Prins KW, Duval S, Markowitz J, Pritzker M, Thenappan T.

Pulm Circ. 2017 Mar 24;7(1):145-155. doi: 10.1086/690017. eCollection 2017 Mar.

8.

Colchicine Depolymerizes Microtubules, Increases Junctophilin-2, and Improves Right Ventricular Function in Experimental Pulmonary Arterial Hypertension.

Prins KW, Tian L, Wu D, Thenappan T, Metzger JM, Archer SL.

J Am Heart Assoc. 2017 May 31;6(6). pii: e006195. doi: 10.1161/JAHA.117.006195.

9.

Pulmonary pulse wave transit time is associated with right ventricular-pulmonary artery coupling in pulmonary arterial hypertension.

Prins KW, Weir EK, Archer SL, Markowitz J, Rose L, Pritzker M, Madlon-Kay R, Thenappan T.

Pulm Circ. 2016 Dec;6(4):576-585. doi: 10.1086/688879.

10.

Microtubule-Mediated Misregulation of Junctophilin-2 Underlies T-Tubule Disruptions and Calcium Mishandling in mdx Mice.

Prins KW, Asp ML, Zhang H, Wang W, Metzger JM.

JACC Basic Transl Sci. 2016 Apr;1(3):122-130. Epub 2016 Apr 18.

11.

World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology.

Prins KW, Thenappan T.

Cardiol Clin. 2016 Aug;34(3):363-74. doi: 10.1016/j.ccl.2016.04.001. Review.

12.

Cardiorenal Syndrome Type 1: Renal Dysfunction in Acute Decompensated Heart Failure.

Prins KW, Thenappan T, Markowitz JS, Pritzker MR.

J Clin Outcomes Manag. 2015 Sep;22(10):443-454.

13.

The Critical Role of Pulmonary Arterial Compliance in Pulmonary Hypertension.

Thenappan T, Prins KW, Pritzker MR, Scandurra J, Volmers K, Weir EK.

Ann Am Thorac Soc. 2016 Feb;13(2):276-84. doi: 10.1513/AnnalsATS.201509-599FR. Review.

14.

Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.

Prins KW, Neill JM, Tyler JO, Eckman PM, Duval S.

JACC Heart Fail. 2015 Aug;3(8):647-53. doi: 10.1016/j.jchf.2015.03.008. Review. Erratum in: JACC Heart Fail. 2015 Oct;3(10):847.

15.

Pulmonary hypertension secondary to heart failure with preserved ejection fraction.

Thenappan T, Prins KW, Cogswell R, Shah SJ.

Can J Cardiol. 2015 Apr;31(4):430-9. doi: 10.1016/j.cjca.2014.12.028. Epub 2015 Jan 6. Review.

PMID:
25840094
16.

Assessing continuous renal replacement therapy as a rescue strategy in cardiorenal syndrome 1.

Prins KW, Wille KM, Tallaj JA, Tolwani AJ.

Clin Kidney J. 2015 Feb;8(1):87-92. doi: 10.1093/ckj/sfu123. Epub 2014 Nov 17.

17.

Quadriceps myopathy caused by skeletal muscle-specific ablation of β(cyto)-actin.

Prins KW, Call JA, Lowe DA, Ervasti JM.

J Cell Sci. 2011 Mar 15;124(Pt 6):951-7. doi: 10.1242/jcs.079848. Epub 2011 Feb 15.

18.

Dystrophin is a microtubule-associated protein.

Prins KW, Humston JL, Mehta A, Tate V, Ralston E, Ervasti JM.

J Cell Biol. 2009 Aug 10;186(3):363-9. doi: 10.1083/jcb.200905048. Epub 2009 Aug 3.

19.

Context-dependent functional substitution of alpha-skeletal actin by gamma-cytoplasmic actin.

Jaeger MA, Sonnemann KJ, Fitzsimons DP, Prins KW, Ervasti JM.

FASEB J. 2009 Jul;23(7):2205-14. doi: 10.1096/fj.09-129783. Epub 2009 Mar 11.

20.

Destabilization of the dystrophin-glycoprotein complex without functional deficits in alpha-dystrobrevin null muscle.

Bunnell TM, Jaeger MA, Fitzsimons DP, Prins KW, Ervasti JM.

PLoS One. 2008 Jul 2;3(7):e2604. doi: 10.1371/journal.pone.0002604.

21.

Skeletal muscle-specific ablation of gamma(cyto)-actin does not exacerbate the mdx phenotype.

Prins KW, Lowe DA, Ervasti JM.

PLoS One. 2008 Jun 11;3(6):e2419. doi: 10.1371/journal.pone.0002419.

Supplemental Content

Loading ...
Support Center